A Phase 3, Open-Label, Randomized 2-arm Study Comparing the Clinical Efficacy and Safety of Niraparib With Temozolomide in Adult Participants With Newly Diagnosed, MGMT Unmethylated Glioblastoma

Sponsor:

IVY

Sponsor Study ID:

P3-24-021

CTO #:

104096

NCT Number:

NCT06388733

Phase:

III

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Brain and Nervous System

Study Objectives:

Test whether niraparib compared with temozolomide significantly extends progression-free survival in participants with newly-diagnosed, MGMT promoter unmethylated glioblastoma. Test whether niraparib compared with temozolomide significantly extends overall survival in participants with newly-diagnosed, MGMT promoter unmethylated glioblastoma.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)